Topadur Pharma

News

8.9.22

TOPADUR has been selected as a TOP 100 Scale-up 2022 with unicorn potential

TOPADUR Pharma AG has been selected among Switzerland's most promising scale-ups in 2022. Huge thanks to everyone of our team, supporters, and partners believing in us along the way!

Please check out the link below.

‍

Download Document Dokument herunterladen https://www.top100startups.swiss/On-the-road-to-growth-Switzerlands-most-promising-scaleups-in-2022 https://www.top100startups.swiss/On-the-road-to-growth-Switzerlands-most-promising-scaleups-in-2022

8.9.22

News

TOPADUR has been selected as a TOP 100 Scale-up 2022 with unicorn potential

We are proud to be recognized as one of Switzerland's most promising scale-ups in 2022.

27.10.20

News

Scientific Publication in Chimia

TOP-N53: A Clinical Drug Candidate for the Treatment of Non-healing Wounds.

15.10.21

Press Release

EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers

EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers in Systemic Sclerosis.

TOPADUR has been selected as a TOP 100 Scale-up 2022 with unicorn potential

TOPADUR has been selected as a TOP 100 Scale-up 2022 with unicorn potential

Scientific Publication in Chimia

EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers

About us

Approach

Disease Areas

Investors

Contact